Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Bowlby, Sarah C ^a   Thomas, Michael J ^a   D'Agostino, Ralph B ^a   Kridel, Steven J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SATURATED FATTY ACID; SHORT CHAIN FATTY ACID; SIRTINOL; SIRTUIN 1; SIRTUIN 3;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CELL STRAIN DU145; CELL STRAIN LNCAP; CELL STRAIN PC 3; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY ACID SYNTHESIS; GENE SILENCING; HUMAN; HUMAN CELL; LIPOGENESIS; PHENOTYPE; PHOSPHOLIPID SYNTHESIS; PROSTATE CANCER; PROTEIN HYPERACETYLATION; REDUCTION; TUMOR CELL;

EID: 84863090408     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040195     Document Type: Article

References (60)

1. Kosaka A, Spivey HO, Gholson RK, (1971) Nicotinate Phosphoribosyltransferase of Yeast. Journal of Biological Chemistry 246: 3277-3283.
2. Preiss J, Handler P, (1957) Enzymatic Synthesis of Nicotinamide Mononucleotide. Journal of Biological Chemistry 225: 759-770.
3. Hasmann M, Schemainda I, (2003) FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis. Cancer Res 63: 7436-7442.
4. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, et al. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences 107: 2037-2042.
5. Yang H, Yang T, Baur JA, Perez E, Matsui T, et al. (2007) Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130: 1095-1107.
6. Soo-Kyung B, Su-Ryun K, Jong Gab K, Jee Yeon K, Tae Hyeon K, et al. (2006) Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS letters 580: 4105-4113.
7. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14: 1431-1437.
8. Reddy P, Umesh S, Balaram T, Tandon A, Pandey P, et al. (2008) PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biology and Therapy 7: 663-668.
9. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, et al. (2011) NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30: 907-921.
10. Bi T-Q, Che X-M, Liao X-H, Zhang D-J, Long H-L, et al. (2011) Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncology Reports 26: 1251-1257.
11. van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, et al. (2007) Extension of Human Cell Lifespan by Nicotinamide Phosphoribosyltransferase. J Biol Chem 282: 10841-10845.
12. Ho C, van der Veer E, Akawi O, Pickering JG, (2009) SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Letters 583: 3081-3085.
13. Borradaile NM, Pickering JG, (2009) Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell 8: 100-112.
14. Olesen U, Christensen M, Bjorkling F, Jaattela M, Jensen P, et al. (2008) Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 367: 799-804.
15. Watson M, Roulston A, Belec L, Billot X, Marcellus R, et al. (2009) The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors. Mol Cell Biol 29: 5872-5888.
16. Fleischer TC, Murphy BR, Flick JS, Terry-Lorenzo RT, Gao Z-H, et al. (2010) Chemical Proteomics Identifies Nampt as the Target of CB30865, An Orphan Cytotoxic Compound. Chemistry & Biology 17: 659-664.
17. Garten A, Petzold S, Korner A, Imai S-i, Kiess W, (2009) Nampt: linking NAD biology, metabolism, and cancer. Trends in Endocrinology & Metabolism 20: 130-138.
18. Bao J, Sack M, (2010) Protein deacetylation by sirtuins: delineating a post-translational regulatory program responsive to nutrient and redox stressors. Cellular and Molecular Life Sciences 67: 3073-3087.
19. Chalkiadaki A, Guarente L, (2012) Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol advance online publication.
20. Kim G-W, Yang X-J, (2011) Comprehensive lysine acetylomes emerging from bacteria to humans. Trends in Biochemical Sciences 36: 211-220.
21. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
22. Zhao S, Xu W, Jiang W, Yu W, Lin Y, et al. (2010) Regulation of Cellular Metabolism by Protein Lysine Acetylation. Science 327: 1000-1004.
23. Hallows WC, Lee S, Denu JM, (2006) Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proceedings of the National Academy of Sciences 103: 10230-10235.
24. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E, (2006) Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proceedings of the National Academy of Sciences 103: 10224-10229.
25. Hallows WC, Yu W, Smith BC, Devires MK, Ellinger JJ, et al. (2011) Sirt3 Promotes the Urea Cycle and Fatty Acid Oxidation during Dietary Restriction. Molecular cell 41: 139-149.
26. Hirschey MD, Shimazu T, Huang J-Y, Schwer B, Verdin E, (2011) SIRT3 Regulates Mitochondrial Protein Acetylation and Intermediary Metabolism. Cold Spring Harbor Symposia on Quantitative Biology.
27. Gerhart-Hines Z, Dominy JE Jr, Blättler SM, Jedrychowski MP, Banks AS, et al. (2011) The cAMP/PKA Pathway Rapidly Activates SIRT1 to Promote Fatty Acid Oxidation Independently of Changes in NAD+. Molecular Cell 44: 851-863.
28. Narala SR, Allsopp RC, Wells TB, Zhang G, Prasad P, et al. (2008) SIRT1 Acts as a Nutrient-sensitive Growth Suppressor and Its Loss Is Associated with Increased AMPK and Telomerase Activity. Molecular Biology of the Cell 19: 1210-1219.
29. Kridel SJ, Lowther WT, Pemble CW IV, (2007) Fatty acid synthase inhibitors: new directions for oncology. Expert Opinion on Investigational Drugs 16: 1817-1829.
30. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF, (1998) Pharmacological Inhibitors of Mammalian Fatty Acid Synthase Suppress DNA Replication and Induce Apoptosis in Tumor Cell Lines. Cancer Research 58: 4611-4615.
31. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, et al. (2006) Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Human Pathology 37: 401-409.
32. An Z, Wang H, Song P, Zhang M, Geng X, et al. (2007) Nicotine-induced Activation of AMP-activated Protein Kinase Inhibits Fatty Acid Synthase in 3T3L1 Adipocytes: A ROLE FOR OXIDANT STRESS. Journal of Biological Chemistry 282: 26793-26801.
33. Witters LA, Watts TD, (1990) Yeast acetyl-CoA carboxylase: In vitro phosphorylation by mammalian and yeast protein kinases. Biochemical and Biophysical Research Communications 169: 369-376.
34. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW, (2004) Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity. Cancer Research 64: 2070-2075.
35. Revollo J, Grimm A, Imai S, (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279: 50754-50763.
36. Seals DF, Azucena EF Jr, Pass I, Tesfay L, Gordon R, et al. (2005) The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell 7: 155-165.
37. Lewis EM, Wilkinson AS, Davis NY, Horita DA, Wilkinson JC, (2011) Nondegradative Ubiquitination of Apoptosis Inducing Factor (AIF) by X-Linked Inhibitor of Apoptosis at a Residue Critical for AIF-Mediated Chromatin Degradation. Biochemistry 50: 11084-11096.
38. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ, (2007) Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells. Cancer Research 67: 1262-1269.
39. Bligh EG DW, (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
40. Rouser G, Siakotos A, Fleischer S, (1966) Quantitative analysis of phospholipids by thin-layer chromatography and phosphorous analysis of spots. Lipids 1: 85-86.
41. DeLong CJ, Baker PRS, Samuel M, Cui Z, Thomas MJ, (2001) Molecular species composition of rat liver phospholipids by ESI-MS/MS: the effect of chromatography. Journal of Lipid Research 42: 1959-1968.
42. Munday MR, Campbell DG, Carling D, Hardie DG, (1988) Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. European Journal of Biochemistry 175: 331-338.
43. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA, (2002) Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1. Journal of Biological Chemistry 277: 45099-45107.
44. Krämer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, et al. (2009) A phosphorylation-acetylation switch regulates STAT1 signaling. Genes & Development 23: 223-235.
45. Kim DH, Kim JM, Lee EK, Choi YJ, Kim CH, et al. (2011) Modulation of FoxO1 phosphorylation/acetylation by baicalin during aging. The Journal of Nutritional Biochemistry.
46. Lavu S, Boss O, Elliott PJ, Lambert PD, (2008) Sirtuins- novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7: 841-853.
47. Taylor D, Maxwell M, Luthi-Carter R, Kazantsev A, (2008) Biological and Potential Therapeutic Roles of Sirtuin Deacetylases. Cellular and Molecular Life Sciences 65: 4000-4018.
48. Rajendran R, Garva R, Krstic-Demonacos M, Demonacos C, (2011) Sirtuins: Molecular Traffic Lights in the Crossroad of Oxidative Stress, Chromatin Remodeling, and Transcription. Journal of Biomedicine and Biotechnology 2011.
49. Peck B, Chen C-Y, Ho K-K, Di Fruscia P, Myatt SS, et al. (2010) SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2. Molecular Cancer Therapeutics 9: 844-855.
50. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, et al. (2010) Inhibition of nicotinamide phosphoribosyl transferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. Journal of Biological Chemistry.
51. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, et al. (2010) De novo Lipogenesis Protects Cancer Cells from Free Radicals and Chemotherapeutics by Promoting Membrane Lipid Saturation. Cancer Research 70: 8117-8126.
52. Scott KEN, Wheeler FB, Thomas MJ, Ntambi JM, Seals DF, et al. (2012) Metabolic regulation of podosomes and invasion by acetyl-CoA carboxylase and de novo lipogenesis. PLoS One In press.
53. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, et al. (2005) Metabolic Signatures Associated with a NAD Synthesis Inhibitor-Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy. Clin Cancer Res 11: 3503-3513.
54. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske A-R, (2007) The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Investigational New Drugs 26: 45-51.
55. Hovstadius P, Larsson R, Jonsson E, Skov T, Kissmeyer A, et al. (2002) A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 8: 2843-2850.
56. Ravaud A, Cerny T, Terret C, Wanders J, Bui B, et al. (2005) Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 41: 702-707.
57. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, et al. (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochemical and Biophysical Research Communications 373: 423-428.
58. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, et al. (2008) Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28: 781-791.
59. Nakane K, Fujita Y, Terazawa R, Atsumi Y, Kato T, et al. (2012) Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. International Journal of Urology 19: 71-79.
60. Jung-Hynes B, Nihal M, Zhong W, Ahmad N, (2009) Role of Sirtuin Histone Deacetylase SIRT1 in Prostate Cancer. Journal of Biological Chemistry 284: 3823-3832.